REGN846

BIOLOGICAL2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Atopic DermatitisHealthyPruritus

Phase 1

Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers

CompletedNCT01209793

Regeneron PharmaceuticalsHealthy

Start: 2010-11-30End: 2011-09-30Updated: 2012-06-01

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

TerminatedNCT01605708

Regeneron PharmaceuticalsAtopic Dermatitis, Pruritus

Start: 2012-06-30End: 2013-04-30Updated: 2013-10-28